Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact

Clinical Pathways

Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact
July 8, 2025
Guest User
New Final Guidance Q&A on RRAs

07/08/2025

-

In June 2025, The US Food and Drug Administration (FDA) released the final guidance titled; “Conducting Remote Regulatory Assessments Questions and Answers” to facilitate understanding about what a remote regulatory assessment (RRA) is expected from establishments when the FDA initiates or requests an RRA.

New Final Guidance Q&A on RRAs
June 23, 2025
Guest User
BIMO Finds Objectionable Conditions During ...

06/23/2025

-

On June 5, 2025, the US Food and Drug Administration (FDA) issued a warning letter and FDA Form 483 to an investigator as a result of objectional conditions observed during a Bioresearch Monitoring Program (BIMO) inspection. According to the letter, the investigator did not adhere to the applicable statutory requirements of Title 21 CFR part 312.60 which states: “An investigator is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations”.

BIMO Finds Objectionable Conditions During Inspection
June 17, 2025
Guest User
FDA shares FAQs on IRBs

06/17/2025

-

In February 2025 the US Food and Drug Administration (FDA) posted a series of frequently asked questions (FAQ) on their website from the public regarding Institutional Review Boards (IRB) and the protection of human subjects in research.

FDA shares FAQs on IRBs
June 3, 2025
Guest User
Final Guidance Released on IRB Written ...

06/03/2025

-

In February 2025, the US Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) Office for Human Research Protection (OHRP) released the final guidance “Institutional Review Board (IRB) Written Procedures.”

Final Guidance Released on IRB Written Procedures
May 30, 2025
Guest User
Now Available: Clinical Pathways’ Major Changes ...

05/30/2025

-

In the ever changing world of clinical research, staying up to date with the latest guidelines and best practices is crucial. Our Major Changes in GCP from ICH E6(R2) to (R3): Road Map is designed for busy professionals who want to deepen their knowledge on GCP to help ensure they meet the highest standards of quality, safety, and compliance.

Sandra Sather
April 8, 2016

Metrics Champion Consortium Partners with Clinical Pathways to Develop On-Demand, eLearning Programs

Sandra Sather
April 8, 2016

Apr 8, 2016

Metrics Champion Consortium (MCC) has teamed up with Clinical Pathways to develop state-of-art, on-demand courses to help organizations and professionals gain expertise in the design and application of performance metrics. 

Sandra Sather
March 22, 2016

Improper disclosure of Research Participants’ protected health information (PHI) results in $3.9 million HIPAA settlement!

Sandra Sather
March 22, 2016

3/22/16

An unprecedented settlement has been agreed to by Feinstein Institute for Medical Research and the U.S. Department of Health and Human Services, Office for Civil Rights (OCR) due to potential HIPAA violations of patients and research participants.

Guest User
March 10, 2016

Pediatric Clinical Trials: Special Considerations and Requirements, Attend the March 14th WEB Session

Guest User
March 10, 2016

3/10/2016

Date: March 14, 2016

Time: 1 p.m. – 2:30 p.m. EDT

Duration: 90 Minutes – Online

Sponsored by Life Science Training Institute

For more information or to sign-up visit this link: http://www.lifesciencetraininginstitute.com/doc/pediatric-clinical-trials-special-considerations-and-requirements-0001

Sandra Sather
March 9, 2016

FDA Warning Letter Issued for "Objectionable Conditions Observed" during inspection!

Sandra Sather
March 9, 2016

3/9/2016

A warning letter issued by Director David Burrow, Pharm.D., J.D. of the U.S. Food and Drug Administration to Gregory J. Tracey, M.D. informs Dr. Tracey of the “objectionable conditions observed during” the course of an FDA inspection conducted at his clinical site between March 25 and April 15, 2015.

Guest User
January 15, 2016

Are you interested in finding out the answers to your TOP GCP questions? If so, Join us this March 16th!

Guest User
January 15, 2016

3/7/2016

Clinical Pathways is partnering with the Life Sciences Training Institute (LSTI) to present a comprehensive, 90 minute course on March 16, 2016, from 1pm- 2:30 pm EST, where we will answer your top five GCP questions!

Newer Posts
Older Posts
 
Archive List
  • 2013 6
  • 2014 31
  • 2015 25
  • 2016 21
  • 2017 31
  • 2018 55
  • 2019 56
  • 2020 63
  • 2021 50
  • 2022 39
  • 2023 27
  • 2024 25
  • 2025 20

Subscribe to Blogs and Newsletters.

By signing up, you agree to our our Privacy Policy. You may unsubscribe from emails at any time.

Thank you! You will receive a confirmation email shortly.

Back to Top
Clinical Pathwaysinfo@clinicalpathwaysresearch.com

Cookie Notice | License Agreement | Privacy Policy | Return Policy | Terms and Conditions | Data Security Policy | Confidentiality Policy

© 2025 Clinical Pathways. All rights reserved.